We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Application of Fibrin Glue in Ocular Surface Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00155402
Recruitment Status : Withdrawn (Short of supply of fibrin glue)
First Posted : September 12, 2005
Last Update Posted : May 29, 2008
Information provided by:
National Taiwan University Hospital

September 8, 2005
September 12, 2005
May 29, 2008
April 2005
Not Provided
cure of the diseases [ Time Frame: 1week, 2 weeks, 3 weeks, 4 weeks ]
  • cure of the diseases
  • visual acuity
  • side effects
Complete list of historical versions of study NCT00155402 on ClinicalTrials.gov Archive Site
  • integrity of the ocular surface [ Time Frame: 1week, 2 weeks, 3 weeks, 4 weeks ]
  • visual acuity [ Time Frame: 1week, 2 weeks, 3 weeks, 4 weeks ]
integrity of the ocular surface
Not Provided
Not Provided
The Application of Fibrin Glue in Ocular Surface Diseases
Phase 1 Study of Applying Fibrin Glue in Patients With Corneal Ulcer or Patients Requiring Wound Closure by Suture
This clinical trial tries to use tissue fibrin glues (Tisseel) to treat various ocular surface diseases or surgeries, which includes pterygium surgery, corneal melting/perforation, Gunderson's flap, conjunctival laceration, and muscle/clinical/filtering surgery.

This clinical trial tries to use tissue fibrin glues (Tisseel) to treat various ocular surface diseases or surgeries. The inclusion criteria are:

  1. ocular surface disease which may need amniotic membrane transplantation (corneal pro epithelization, pterygium surgery, etc)
  2. infectious or noninfectious corneal ulcer with perforation less than 3 mm
  3. conjunctival transplantation/suture
  4. corneal surgeries which can be treated by conventional suture technique or application with cyanoacrylic acid tissue glues.

Informed consents will be obtained from the patients before applications. After surgeries, topical steroids and antibiotics will be used, and therapeutic contact lens will be used. The patients will be followed up for at least three months.

Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Pterygium
  • Corneal Ulcer
Drug: tissue fibrin glue application (Tisseel)
Apply several droplets within several seconds to several minutes
Experimental: 1
Use of fibrin glue after corneal surgery or transplantation
Intervention: Drug: tissue fibrin glue application (Tisseel)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2008
Not Provided

Inclusion Criteria:

  • Ocular surface diseases, which are expected to be treated by tissue fibrin glues

Exclusion Criteria:

  • Pregnancy
  • Children younger than 3 years old
Sexes Eligible for Study: All
3 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Wei-Li Chen/Assistant Professor, National Taiwan University, Department of Ophthalmology
National Taiwan University Hospital
Not Provided
Principal Investigator: Fung-Rong Hu, MD National Taiwan University Hospital
National Taiwan University Hospital
March 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP